In a patient who has developed akathisia while on risperidone and olanzapine, should brexpiprazole be recommended?

Brexpiprazole Should NOT Be Recommended in This Patient

In a patient who has already developed akathisia on both risperidone and olanzapine, brexpiprazole is a poor choice and should be avoided. This patient has demonstrated a clear propensity for developing akathisia with antipsychotics, and brexpiprazole carries a significant risk of causing this same adverse effect.

Why Brexpiprazole Is Problematic Here

High Akathisia Risk Profile

Brexpiprazole has a well-documented akathisia risk that is dose-dependent and clinically significant:

• Akathisia incidence of 9% in depression augmentation trials (compared to 2% with placebo) 1
• Akathisia incidence of 6% in schizophrenia trials (compared to 5% with placebo) 1
• Meta-analysis data shows brexpiprazole has an akathisia incidence of 10.0%, which is higher than iloperidone (3.9%) and asenapine (6.8%) 2
• The risk ratio for akathisia with brexpiprazole versus placebo is 3.39, meaning patients are more than 3 times as likely to develop akathisia 3
• Akathisia risk increases with dose: at 3 mg daily, akathisia incidence reaches 14% 1

Pattern Recognition

This patient has already failed two antipsychotics due to akathisia. Adding a third medication with substantial akathisia risk (particularly a D2 partial agonist like brexpiprazole) is clinically unwise and likely to repeat the same problem.

What Should Be Done Instead

Follow Guideline-Based Switching Strategy

The most recent 2025 INTEGRATE guidelines provide clear direction 4:

For akathisia management, the recommended approach is:

1. Switch to quetiapine or olanzapine as first-line options
2. Alternatively, use adjunctive propranolol (10-30 mg, 2-3 times daily)

However, since this patient already failed olanzapine due to akathisia, quetiapine becomes the preferred switch option 4.

Alternative Evidence-Based Approaches

If switching antipsychotics is necessary, consider medications with lower akathisia profiles:

• Quetiapine: Specifically recommended for akathisia-prone patients 4
• Iloperidone: Has the lowest akathisia incidence (3.9%) among newer antipsychotics 2
• Clozapine: If the patient meets criteria for treatment resistance (failed 2 adequate trials), clozapine should be considered 4, 5

Pharmacological Management Strategy

If continuing with current medication is necessary:

• Add propranolol 10-30 mg two to three times daily for akathisia management 4
• Consider benzodiazepines as an alternative adjunctive treatment 5

Critical Clinical Pitfall

Do not assume that because brexpiprazole is a "newer" or "cleaner" D2 partial agonist it will be better tolerated. While brexpiprazole has lower akathisia rates than cariprazine (17.2%) and lurasidone (12.7%) 2, it still carries substantial risk—especially in a patient with demonstrated vulnerability to this side effect. The FDA label explicitly warns that akathisia incidence is dose-related and occurs in up to 14% of patients at higher doses 1.

Bottom Line Algorithm

For this akathisia-prone patient:

1. First choice: Switch to quetiapine (lowest akathisia risk among effective options)
2. Second choice: If treatment resistance is confirmed (≥2 failed adequate trials), proceed to clozapine with metformin 4
3. Third choice: Add propranolol or benzodiazepine to current regimen if switching is not feasible
4. Avoid: Brexpiprazole, cariprazine, lurasidone, and aripiprazole (all have significant akathisia risk)

The 2020 APA guidelines support switching to another antipsychotic medication as a primary strategy for managing akathisia 5, and the 2025 INTEGRATE guidelines specifically name quetiapine as the preferred alternative 4.